We examine the role of the cholecystokinin-2 receptor (CCK2R) in MTC nuclear imaging, and discuss methods of targeting it more efficiently.
We explore various issues related to nephrotoxicity induced by tyrosine kinase inhibitors in patients with medullary thyroid carcinoma.
We review the genetics of both sporadic and familial medullary thyroid carcinoma, and discuss their implications for clinical management.
There are many different strands of cancer research we can be sure are being conducted simultaneously. Some members of the public may imagine cancer research to be all about creating a myriad of new therapies in the hopes that one will prove to be able to effectively “cure” cancer. However, there is a type of…
We describe the common clinical presentation of MTC in children and discuss the ethical dilemmas of prophylactic thyroidectomy.
Editor’s Note: In this Q&A, Patient Perspectives columnist Christine Pudel, RN, answers questions from her editor. A 30-year-old wife, mother to a son, and a registered nurse, Christine was diagnosed with medullary thyroid cancer (MTC) in 2016 and has undergone 2 surgeries, as well as radiation therapy. Her columns uniquely capture a life with MTC…
What are the clinical benefits and limitations of calcitonin as a biomarker for medullary thyroid carcinoma? We explore this, and more.
We explore the current surgical guidelines for medullary thyroid carcinoma, as well as the role of peptide receptor radionuclide therapy.
The only curative treatment for medullary thyroid carcinoma (MTC) is total thyroidectomy and lymph node dissection. However, even with patients in whom a radical surgical approach has been taken, serum calcitonin levels can be persistently high in macroscopic MTC. In a 10-year period, 50% of patients undergo relapse despite surgery. Distant metastases in the lungs,…
The development of drugs that target RET signaling has brought about demonstrable clinical benefits to MTC patients, but there is still more to learn.